Radiotherapy and Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.

Trial Profile

Radiotherapy and Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Olaparib (Primary)
  • Indications Adenocarcinoma; Oesophageal cancer
  • Focus Adverse reactions; Biomarker
  • Acronyms ROCOCO
  • Most Recent Events

    • 25 Feb 2016 Planned End Date changed from 1 Aug 2018 to 1 Sep 2016 as reported by United Kingdom Clinical Research Network.
    • 02 Apr 2015 Accrual to date is 27% according to United Kingdom Clinical Research Network record.
    • 11 Mar 2015 Accrual to date is 25% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top